Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593764 | 0.85 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL2223682 | 0.81 | LMNA (0.52) | DRD2DRD4DRD3LMNAHDAC1 | |
| SCHEMBL1051422 | 0.81 | HDAC1 (0.46) | HDAC1HDAC8HDAC6PPARGPPARA | |
| SCHEMBL1047872 | 0.81 | HDAC1 (0.50) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL4034904 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL3126496 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL5544565 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL202789 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL12432902 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL1436020 | 0.81 | DRD2 (0.58) | DRD2DRD4DRD3FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| EP-1425014-B1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6884812-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1425014-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2003020269-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | DRD2 3068/4885DRD4 3046/4885DRD3 2715/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | DRD2 3139/4885DRD4 3096/4885DRD3 2751/4885 |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, LIPA | DRD2 3159/4885DRD4 3002/4885DRD3 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.